Taking cholesterol-lowering drugs may also reduce the risk of dying from prostate cancer: Study
May 1, 2013 by admin · Leave a Comment
Men with prostate cancer who take cholesterol-lowering drugs called statins are significantly less likely to die from their cancer than men who don’t take such medication, according to study led by researchers at Fred Hutchinson Cancer Research Center. The findings are published online today in The Prostate.
Virus shows promise as prostate cancer treatment
February 25, 2013 by admin · Leave a Comment
A recombinant Newcastle disease virus kills all kinds of prostate cancer cells, including hormone resistant cells, but leaves normal cells unscathed, according to a paper published online ahead of print in the Journal of Virology. A treatment for prostate cancer based on this virus would avoid the adverse side effects typically associated with hormonal treatment for prostate cancer, as well as those associated with cancer chemotherapies generally, says corresponding author Subbiah Elankumaran of Virginia Polytechnic Institute, Blacksburg. The modified virus is now ready to be tested in preclinical animal models, and possibly in phase I human clinical trials.
Mushroom-supplemented soybean extract shows therapeutic promise for advanced prostate cancer
February 20, 2013 by admin · Leave a Comment
A natural, nontoxic product called genistein-combined polysaccharide, or GCP, which is commercially available in health stores, could help lengthen the life expectancy of certain prostate cancer patients, UC Davis researchers have found.
How prostate cancer therapies compare by cost and effectiveness
January 4, 2013 by admin · Leave a Comment
The most comprehensive retrospective study ever conducted comparing how the major types of prostate cancer treatments stack up to each other in terms of saving lives and cost effectiveness is reported this week by a team of researchers at the University of California, San Francisco (UCSF).
Drug shows promise in prostate cancer spread to bone
December 4, 2012 by admin · Leave a Comment
A new drug demonstrated dramatic and rapid effects on prostate cancer that had spread to the bone, according to a study reported by University of Michigan Comprehensive Cancer Center researchers.
About two-thirds of patients treated with cabozantinib had improvements on their bone scans, with 12 percent seeing complete resolution of uptake on bone scan. Bone scans assess the degree to which cancer is in the bone; improvements on these scans suggest a response to the drug.
Scientists develop ‘barcode’ blood test for aggressive prostate cancer
October 8, 2012 by admin · Leave a Comment
Scientists have designed a blood test that reads genetic changes like a barcode ? and can pick out aggressive prostate cancers by their particular pattern of gene activity.
A team at The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust found reading the pattern of genes switched on and off in blood cells could accurately detect which advanced prostate cancers had the worst survival.
New drugs, new ways to target androgens in prostate cancer therapy
June 20, 2012 by admin · Leave a Comment
Prostate cancer cells require androgens including testosterone to grow. A recent review in the British Journal of Urology International describes new classes of drugs that target androgens in novel ways, providing alternatives to the traditional methods that frequently carry high side effects.
Study shows botanical formula fights prostate cancer
April 9, 2012 by admin · Leave a Comment
A non-toxic, botanical formula controls aggressive human prostate tumors in mice, according to a peer-reviewed study in the The International Journal of Oncology. Researchers at Indiana University, Methodist Research Institute, showed the prostate formula significantly suppresses tumor growth in aggressive, hormone-refractory (androgen-independent) human prostate cancer cells. The study also demonstrated the formula has no toxic side effects, even at high dosages.
Early clinical data show galeterone safe, effective against prostate cancer
March 30, 2012 by admin · Leave a Comment
Patients with castration-resistant prostate cancer had limited side effects and in many cases a drop in prostate-specific antigen expression with galeterone (TOK-001), a small-molecule oral drug, according to phase I data presented at the AACR Annual Meeting 2012, held here March 31 – April 4.
Circumcision may help protect against prostate cancer
March 11, 2012 by admin · Leave a Comment
A new analysis led by researchers at Fred Hutchinson Cancer Research Center has found that circumcision before a male’s first sexual intercourse may help protect against prostate cancer. Published early online in Cancer, a peer-reviewed journal of the American Cancer Society, the study suggests that circumcision can hinder infection and inflammation that may lead to this malignancy.
